AffiliationDepartment of Medicine, Cork University Hospital, Wilton.
MeSHAdrenocortical Hyperfunction/blood/chemically induced
Antineoplastic Agents, Hormonal/administration & dosage/*adverse effects
Breast Neoplasms/drug therapy
Cushing Syndrome/blood/*chemically induced
Medroxyprogesterone Acetate/administration & dosage/*adverse effects
Megestrol/administration & dosage/adverse effects/*analogs & derivatives
Muscle Weakness/chemically induced
Progesterone Congeners/administration & dosage/*adverse effects
MetadataShow full item record
CitationIr J Med Sci. 1995 Oct-Dec;164(4):274-5.
JournalIrish journal of medical science
AbstractWe report 3 patients where Medroxyprogesterone Acetate (MPA = Provera) and Megestrol Acetate (Megace) in doses used for therapy of breast cancer, caused clinical hypercortisolism and Cushing's syndrome. Studies of the toxicity of Medroxyprogesterone Acetate list the commonest adverse events at 500 mg/day as weight gain, water retention, increased blood pressure, tremor, moon face, sweating, muscle cramps, vaginal bleeding and increased appetite. Glucocorticoid-like effects are seen in up to 30% of patients treated for longer than 6 weeks with mostly large doses of the order of 1500 mg/day but Cushing's syndrome has been reported in patients taking 400 mg/day. Neither the glucocorticoid-like effects or Cushing's syndrome have been previously observed with Megestrol Acetate. In the elderly female population receiving progestogens for neoplastic disease the progestogen itself could be an appreciable cause of morbidity both by causing glucocorticoid-like effects and Cushing's syndrome but also by lack of awareness of the danger of sudden withdrawal of these compounds when the hypothalmic-pituitary-adrenal (HPA) axis is suppressed. The signs and symptoms could be easily overlooked unless appropriate testing for Cushing's syndrome is carried out. While the progestogen may have to be continued indefinitely a dose decrease may be feasible with reduction of morbidity.
- Megestrol-induced Cushing's syndrome.
- Authors: Steer KA, Kurtz AB, Honour JW
- Issue date: 1995 Jan
- Medroxyprogesterone acetate induced Cushing's syndrome.
- Authors: Shotliff K, Nussey SS
- Issue date: 1997 Sep
- Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate.
- Authors: Malik KJ, Wakelin K, Dean S, Cove DH, Wood PJ
- Issue date: 1996 May
- Medroxyprogesterone induced Cushing's syndrome.
- Authors: Learoyd D, McElduff A
- Issue date: 1990 Dec
- Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome.
- Authors: Seo Y, Jeong EG, Kim ES
- Issue date: 2015 Nov